Pharmaceutical companies Eli Lilly & Co. and AstraZeneca PLC are completely scrapping trials of an experimental drug they were co-developing for the treatment of Alzheimer’s. It is an unsurprising announcement among various other disappointing efforts to close the gap to the finish line in the race against the debilitating disease.
The decision to pull the plug was made after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, would not achieve their original goals, according to the Wall Street Journal. Although there were no safety concerns with the trial, the companies said the treatments were not working as they had originally expected.
They will however, continue the 2014 alliance and work together to create another experimental drug. Failure to produce an adequate drug has largely been attributed to a lack of understanding around the science of the brain and while there are currently treatments to alleviate symptoms, nothing has been effective in slowing the progression of the disease.
Earlier this year, Johnson & Johnson also discontinued trials for their own research to find a disease-modifying drugs due to safety issues with the liver.
For more insight on Alzheimer’s experimental drugs and challenges, visit BioPharma Dive’s article.